Drug Trial Radar · NCT00239642
Safety and Efficacy of Iron Sucrose in Children
Last checked: Nov 20, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Jul 2005
Primary completion
Jan 2009
Study completion Apr 2010
Sponsor
- Lead sponsor
- American Regent, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison of three potential iron sucrose maintenance regimens in pediatric chronic kidney disease (CKD) patients
Conditions
- Anemia
- Chronic Kidney Disease
Interventions
Venofer (iron sucrose injection)Drug
0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Venofer (iron sucrose injection)Drug
1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Venofer (iron sucrose injection)Drug
2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Profile: Number of Subjects Experiencing at Least 1 Adverse EventTime frame: baseline through week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Luitpold Pharmaceutials
Norristown, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.